Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit

Sisli Hamidiye Etfal Training and Research Hospital100 enrolled

Overview

Effect of Favipiravir and Lopinavir-Ritonavir on Mortality in a Tertiary Center Intensive Care Unit: Single Center Experience

Many agents have been given for treatment of COVID-19 infection. "Covid-19 Diagnosis and Treatment Guideline" by Ministry of Health was advised nationwide use of favipiravir or lopinavir-ritonavir although evidence was scarce for the nationwide use of lopinavir-ritonavir or favipiravir to treat COVID-19 at the time of publication date of detailed guideline Favipiravir is a RNA dependent RNA polymerase inhibitor and approved for treatment of influenza in Japan at 2014 The aim of the study was to compare ICU and hospital mortality in patients with favipiravir or lopinavir-ritonavir treatment and compare other laboratory parameters in patients treated with these two antiviral agents.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Mortality Intensive Care Unit

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 Years and older Exclusion Criteria: * patients younger than 18 years old * patients who have received both lopinavir-ritonavir and favipiravir sepuentially

Locations (1)

SisliHamidiye Etfal Education and Training Hospital

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

Mortality for ICU

If the patient dies, we have reached an outcome

Time frame: 14 days

hospital stay

If the hospital stay exceeds 14 days, we have reached an outcome

Time frame: 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.